Capsaicin patch license extension application withdrawn
21st March 2012
Astellas Pharma has withdrawn its application to the European Medicines Agency (EMA) for a license extension for Qutenza® (capsaicin 8% transdermal patch). The application was to extend the marketing authorization for Qutenza® to all adult patients with exclusion of patients with pain caused by diabetes.
The withdrawal was based on the Committee for Medicinal Products for Human Use (CHMP)'s view that the data provided would not allow the committee to conclude on a positive benefit-risk balance.
Qutenza® continues to be authorized for the treatment of peripheral neuropathic pain (PNP) in non-diabetic adults either alone or in combination with other medicinal products for pain.
- Domperidone restricted to a POM
- Liverpool Care pathway replaced by five Priorities for Care
- CQC annual report: safer management of controlled drugs
- Sativex approved in Wales to treat MS symptoms on NHS
- Ketamine rescheduling consultation
- Levobupivacaine 250mg/200mL epidural infusion bags supply problem
- Dexamfetamine sulfate oral solution now authorized
- Cochrane review: Levetiracetam for neuropathic pain in adults
- Cochrane review: Topical lidocaine for neuropathic pain in adults
- PCF4+ 2013 e-book now half price!